Daniel J. George, MD

Daniel J. George, MD, medical oncologist, Duke Cancer Institute, says that clinicians who treat prostate cancer have devoted the past 70 years to hormone therapy and androgen deprivation therapy, particularly for patients with metastatic disease. However, the emergence of agents like docetaxel, abiraterone acetate (Zytiga), and androgen receptor (AR) antagonists, like apalutamide (Erleada) and enzalutamide (Xtandi), have changed the landscape.

Now that clinical studies have shown how all of these agents can benefit patients with prostate cancer, oncologists will have the opportunity to use some agents earlier and combinations with novel agents to increase benefit in the post-AR and post-chemotherapy settings. The number of possibilities is making room for more clinical trials that will help to prolong life in patients with prostate cancer.

The most exciting thing about the evolving landscape is that some of these agents will move on into the curative setting, says George.

Videos

Daniel J. George, MD, says that clinicians who treat prostate cancer have devoted the past 70 years to hormone therapy and androgen deprivation therapy, particularly for patients with metastatic disease. However, the emergence of agents like docetaxel, abiraterone acetate, and androgen receptor antagonists, like apalutamide and enzalutamide, have changed the landscape.<br />
&nbsp;

The Evolving Treatment Landscape of Prostate Cancer

Daniel J. George, MD, professor of medicine and surgery at Duke Cancer Institute, discusses his rationale for choosing patients with renal cell carcinoma (RCC) that should receive adjuvant sunitinib (Sutent) therapy.

Most importantly, George says to consider which patients will most likely benefit from this therapy. He says that by enriching patients at higher risk, physicians can focus even more on the patients more likely to benefit. When faced with a patient with node-positive disease, T4 disease, or high-grade or poor performance status disease, George is more likely to offer them this adjuvant therapy.

The challenge to overcome with these patients is deciding whether or not they can tolerate sunitinib for a year. Particularly with older patients or those that may be a little more on the fence, George will still discuss the option with them because of their higher risk of recurrence. There is a greater benefit associated with this adjuvant therapy.

See more from Targeted Oncology's discussion with Daniel J. George, MD, on the S-TRAC trial in renal cell carcinoma here:

https://www.targetedonc.com/news/an-overview-of-strac-trial-analyses-in-patients-with-highrisk-rcc

Daniel J. George, MD, professor of medicine and surgery at Duke Cancer Institute, discusses his rationale for choosing patients with renal cell carcinoma that should receive adjuvant sunitinib therapy.&nbsp;

Daniel J. George, MD | Authors

Articles

The Evolving Treatment Landscape of Prostate Cancer

Selecting Patients With Renal Cell Carcinoma for Adjuvant Sunitinib Therapy